Literature DB >> 2971721

Possible role of human lymphocyte receptor for IgE (CD23) or its soluble fragments in the in vitro synthesis of human IgE.

M Sarfati1, G Delespesse.   

Abstract

The present study demonstrates that human rIL-4 is capable of inducing the secretion of IgE by PBMC. At a concentration of 200 U/ml, an IgE response was observed in 11/26 cultures of PBMC from normal donors and in 12/15 cultures from allergic individuals. The same rIL-4-stimulated cells released significant amounts of IgE-binding factors (IgE-BF) in their culture supernatant. These IgE-BF were shown for the first time to bind simultaneously to some mAb against Fc epsilon R II (mAbER) and to soluble IgE. The lack of correlation between the rIL-4-induced secretion of IgE-BF and IgE indicates that the production of IgE-BF or the expression of Fc epsilon R II is not the only factor involved in the induction of IgE synthesis by rIL-4. However, the observation that mAbER suppressed the rIL-4-induced IgE synthesis strongly suggests that either Fc epsilon R II or IgE-BF are necessary for an IgE response. Finally, the spontaneous in vitro synthesis of IgE by enriched B cell preparations isolated from atopic donors was suppressed in an isotype-specific manner by the same mAbER or by their F(ab')2 fragments. These observations suggest that the ongoing IgE synthesis by in vivo pre-activated B cells is also regulated by IgE-BF or Fc epsilon R II. It is concluded that Fc epsilon R II or IgE-BF play an essential role both in the induction of IgE synthesis by normal B cells and in the ongoing IgE synthesis by in vivo activated B cells from allergic donors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971721

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells.

Authors:  S N Karagiannis; J K Warrack; K H Jennings; P R Murdock; G Christie; K Moulder; B J Sutton; H J Gould
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Partial characterization of natural and recombinant human soluble CD23.

Authors:  K Rose; G Turcatti; P Graber; S Pochon; P O Regamey; K U Jansen; E Magnenat; N Aubonney; J Y Bonnefoy
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

Review 3.  The role of interleukin-4 in IgE and IgG subclass formation.

Authors:  H L Spiegelberg
Journal:  Springer Semin Immunopathol       Date:  1990

Review 4.  Regulation of IgE synthesis in humans.

Authors:  D Vercelli; R S Geha
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

5.  Elevated soluble CD23 levels in the sera from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

Review 6.  The receptor for the Fc region of IgE.

Authors:  A D Keegan; D H Conrad
Journal:  Springer Semin Immunopathol       Date:  1990

7.  Characterization of a Leishmania tropica antigen that detects immune responses in Desert Storm viscerotropic leishmaniasis patients.

Authors:  D C Dillon; C H Day; J A Whittle; A J Magill; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

8.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

9.  IL-4 production is increased in cigarette smokers.

Authors:  K A Byron; G A Varigos; A M Wootton
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

10.  Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes.

Authors:  M Kiniwa; M Gately; U Gubler; R Chizzonite; C Fargeas; G Delespesse
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.